UNITY Biotechnology stock loses 29% as the mid-stage DME study of the lead candidate, UBX1325, fails to achieve statistical ...

Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...

Opthea's Phase 3 COAST trial for wet AMD did not meet its primary endpoint, raising financial concerns as the company faces ...

"Regeneron has invested many years of effort into its design and development of EYLEA® (aflibercept) Injection 2 mg. This work has resulted in numerous patents, reflecting our important research ...

Alvotech will conduct a business update conference call and live webcast on Thursday March 27, 2025, at 8:00 am ET (12:00pm ...

intravitreal UBX1325 compared with Regeneron’s REGN Eylea (aflibercept) in diabetic macular edema (“DME”) patients. The primary efficacy endpoint of the phase IIb ASPIRE study is ...

The investigators retrospectively evaluated 126 consecutive treatment-naïve nAMD patients (126 eyes) who received a loading ...

Australian-US biotech Opthea Ltd has reported disappointing phase 3 results with its lead drug for vision-robbing disease wet age-related macular degeneration (AMD), throwing its future into doubt.

The Australian biotech could potentially be on the hook for more than $1bn after sozinibercept failed to show impact over ...